帕金森病伴认知障碍患者的血浆胶质纤维酸性蛋白及其预测向痴呆转化的潜力。
Plasma GFAP in Parkinson's disease with cognitive impairment and its potential to predict conversion to dementia.
作者信息
Tang Yilin, Han Linlin, Li Shiyu, Hu Tianyu, Xu Zhiheng, Fan Yun, Liang Xiaoniu, Yu Huan, Wu Jianjun, Wang Jian
机构信息
Department of Neurology and National Research Center for Aging and Medicine & National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, China.
出版信息
NPJ Parkinsons Dis. 2023 Feb 9;9(1):23. doi: 10.1038/s41531-023-00447-7.
Glial fibrillary acidic protein (GFAP) has been suggested as a biomarker for reactive astrogliosis. We measured the levels of plasma GFAP by Simoa in 60 patients with PD with normal cognition, 63 with mild cognitive impairment (PD-MCI), 24 with dementia (PDD) and 15 healthy controls. A subgroup of patients with PD-MCI (n = 31) was followed up for 4.1 ± 2.3 years. Compared with healthy controls, plasma GFAP levels were elevated in patients with PDD (adjusted P < 0.001) and PD-MCI (adjusted P = 0.013) and were negatively correlated with the Mini Mental State Examination (MMSE) score in PD participants. Plasma GFAP predicted MCI-to-dementia conversion with an AUC of 0.90, higher than NfL, Tau and pTau181. Our results support that plasma GFAP has potential value for distinguishing patients with PDD, and predicting MCI-to-dementia conversion in PD.
胶质纤维酸性蛋白（GFAP）已被提议作为反应性星形胶质细胞增生的生物标志物。我们通过单分子阵列免疫检测技术（Simoa）测量了60例认知正常的帕金森病（PD）患者、63例轻度认知障碍（PD-MCI）患者、24例痴呆（PDD）患者及15名健康对照者的血浆GFAP水平。对一组PD-MCI患者（n = 31）进行了4.1±2.3年的随访。与健康对照者相比，PDD患者（校正P < 0.001）和PD-MCI患者（校正P = 0.013）的血浆GFAP水平升高，且与PD参与者的简易精神状态检查表（MMSE）评分呈负相关。血浆GFAP预测MCI向痴呆转化的曲线下面积（AUC）为0.90，高于神经丝轻链（NfL）、 Tau蛋白和磷酸化Tau蛋白181位点（pTau181）。我们的结果支持血浆GFAP在区分PDD患者以及预测PD患者MCI向痴呆转化方面具有潜在价值。
Zotero 插件